JP2022510430A5 - - Google Patents
Info
- Publication number
- JP2022510430A5 JP2022510430A5 JP2021531906A JP2021531906A JP2022510430A5 JP 2022510430 A5 JP2022510430 A5 JP 2022510430A5 JP 2021531906 A JP2021531906 A JP 2021531906A JP 2021531906 A JP2021531906 A JP 2021531906A JP 2022510430 A5 JP2022510430 A5 JP 2022510430A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- disease
- pharmaceutically acceptable
- halo
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862775558P | 2018-12-05 | 2018-12-05 | |
| US62/775,558 | 2018-12-05 | ||
| PCT/US2019/064514 WO2020117961A1 (en) | 2018-12-05 | 2019-12-04 | Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022510430A JP2022510430A (ja) | 2022-01-26 |
| JP2022510430A5 true JP2022510430A5 (enExample) | 2022-12-12 |
| JP7607562B2 JP7607562B2 (ja) | 2024-12-27 |
Family
ID=69006035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531906A Active JP7607562B2 (ja) | 2018-12-05 | 2019-12-04 | モルホリニル、ピペラジニル、オキサゼパニル及びジアゼパニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12319679B2 (enExample) |
| EP (2) | EP3891146B1 (enExample) |
| JP (1) | JP7607562B2 (enExample) |
| AR (1) | AR117252A1 (enExample) |
| ES (1) | ES2968733T3 (enExample) |
| MA (1) | MA54384A (enExample) |
| TW (1) | TW202039482A (enExample) |
| UY (1) | UY38498A (enExample) |
| WO (1) | WO2020117961A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| WO2025247394A1 (zh) * | 2024-05-31 | 2025-12-04 | 纽欧申医药(上海)有限公司 | 含氮杂环化合物、其药物组合物及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| PT2970272T (pt) * | 2013-03-14 | 2019-06-05 | Merck Patent Gmbh | Inibidores de glicosidase |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| US20190359609A1 (en) | 2016-12-16 | 2019-11-28 | Janssen Pharmaceutica Nv | Bicyclic oga inhibitor compounds |
| EP3555087A1 (en) * | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| TWI654978B (zh) | 2017-01-27 | 2019-04-01 | 美商美國禮來大藥廠 | 5－甲基－1,2,4－二唑－3－基化合物 |
| WO2018154133A1 (en) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
-
2019
- 2019-12-04 ES ES19828102T patent/ES2968733T3/es active Active
- 2019-12-04 WO PCT/US2019/064514 patent/WO2020117961A1/en not_active Ceased
- 2019-12-04 US US17/311,232 patent/US12319679B2/en active Active
- 2019-12-04 MA MA054384A patent/MA54384A/fr unknown
- 2019-12-04 JP JP2021531906A patent/JP7607562B2/ja active Active
- 2019-12-04 TW TW108144351A patent/TW202039482A/zh unknown
- 2019-12-04 EP EP19828102.4A patent/EP3891146B1/en active Active
- 2019-12-04 AR ARP190103550A patent/AR117252A1/es unknown
- 2019-12-04 EP EP23199729.7A patent/EP4327814A3/en not_active Withdrawn
- 2019-12-04 UY UY0001038498A patent/UY38498A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518340A5 (enExample) | ||
| JP2022500472A5 (enExample) | ||
| Asahina et al. | Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin | |
| Sedelmeier et al. | Efficient copper-catalyzed N-arylation of sulfoximines with aryl iodides and aryl bromides | |
| Klapars et al. | A general and efficient copper catalyst for the amidation of aryl halides | |
| Fang et al. | Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives | |
| Bhunia et al. | N, N′-Bisoxalamides enhance the catalytic activity in Cu-catalyzed coupling of (Hetero) Aryl bromides with anilines and secondary amines | |
| JP2019506430A5 (enExample) | ||
| JP2022510430A5 (enExample) | ||
| JP2009530306A5 (enExample) | ||
| Aithagani et al. | Metal-free, phosphonium salt-mediated sulfoximination of azine N-oxides: Approach for the synthesis of N-azine sulfoximines | |
| JP2011515482A5 (enExample) | ||
| JP2014524911A5 (enExample) | ||
| JP2020519606A5 (enExample) | ||
| JP2020535165A5 (enExample) | ||
| JP2007524710A5 (enExample) | ||
| CA2556653A1 (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | |
| JP2020500215A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| CA2570197A1 (en) | Nk1 antagonists | |
| JP2022533939A5 (enExample) | ||
| JP2022504650A5 (enExample) | ||
| JP2022519639A5 (enExample) | ||
| JP2021523934A5 (enExample) | ||
| JP2023501949A5 (enExample) |